Table 1.
Demographic characteristics of the training and test samples
| Test set (available data) (n = 12) | Training set only (n = 136) | Total (n = 148) | |
|---|---|---|---|
| Age (years) | |||
| Median | 44 | 46 | 46 |
| Min-max | 30-82 | 27-82 | 27-82 |
| Q1 (first quartile) - Q3 (third quartile) | 41.5-60.5 | 38-56 | 38-56 |
| 20-29 | 0 (0.0%) | 5 (3.7%) | 5 (3.4%) |
| 30-39 | 2 (16.7%) | 39 (28.7%) | 41 (27.7%) |
| 40-49 | 6 (50.0%) | 42 (30.9%) | 48 (32.4%) |
| 50-59 | 1 (8.3%) | 25 (18.4%) | 26 (17.6%) |
| 60-69 | 1 (8.3%) | 17 (12.5%) | 18 (12.2%) |
| 70-79 | 1 (8.3%) | 7 (5.1%) | 8 (5.4%) |
| 80-89 | 1 (8.3%) | 1 (0.7%) | 2 (1.4%) |
| Ethnicity | |||
| Hispanic | 2 (16.7%) | 27 (19.9%) | 29 (19.6%) |
| Non-Hispanic | 10 (83.3%) | 106 (77.9%) | 116 (78.4%) |
| Unknown/not reported | 0 (0.0%) | 3 (2.2%) | 3 (2.0%) |
| Race | |||
| Unknown/not reported | 0 (0.0%) | 4 (2.9%) | 4 (2.7%) |
| Asian | 1 (8.3%) | 2 (1.5%) | 3 (2.0%) |
| Black/African American | 2 (16.7%) | 15 (11.0%) | 17 (11.5%) |
| American Indian/Alaskan | 0 (0.0%) | 2 (1.5%) | 2 (1.4%) |
| More than 1 race | 0 (0.0%) | 1 (0.7%) | 1 (0.7%) |
| White | 9 (75.0%) | 112 (82.4%) | 121 (81.8%) |
| Performance status | |||
| 0 | 9 (75.0%) | 110 (80.9%) | 119 (80.4%) |
| 1 | 3 (25.0%) | 26 (19.1%) | 29 (19.6%) |
| Histology | |||
| Adenocarcinoma, unsp. | 0 (0.0%) | 29 (21.3%) | 29 (19.6%) |
| Adenosquamous | 0 (0.0%) | 4 (2.9%) | 4 (2.7%) |
| Squamous cell carcinoma | 12 (100.0%) | 103 (75.7%) | 115 (77.7%) |
| FIGO stage | |||
| I | 1 (8.3%) | 28 (20.6%) | 29 (19.6%) |
| II | 7 (58.3%) | 77 (56.6%) | 84 (56.8%) |
| III | 3 (25.0%) | 23 (16.9%) | 26 (17.6%) |
| IV | 1 (8.3%) | 8 (5.9%) | 9 (6.1%) |
| Site of disease | |||
| Cervix | 11 (91.7%) | 128 (94.1%) | 139 (93.9%) |
| Vagina | 1 (8.3%) | 8 (5.9%) | 9 (6.1%) |
| Planned brachytherapy | |||
| HDR | 12 (100.0%) | 132 (97.1%) | 144 (97.3%) |
| LDR | 0 (0.0%) | 4 (2.9%) | 4 (2.7%) |
| Planned IG-IMRT | |||
| No | 0 (0.0%) | 33 (24.3%) | 33 (22.3%) |
| Yes | 12 (100.0%) | 103 (75.7%) | 115 (77.7%) |
| Randomized treatment | |||
| RT + CIS | 4 (33.3%) | 70 (51.5%) | 74 (50.0%) |
| RT + CIS + 3AP | 8 (66.7%) | 66 (48.5%) | 74 (50.0%) |
Abbreviations: 3AP = Triapine; CIS = cisplatin; FIGO = International Federation of Gynecology and Obstetrics; HDR = high-dose-rate; IG-IMRT = image guided intensity modulated radiation therapy; LDR = low dose rate; RT = radiation therapy.